everybody. morning, good and Martine, Thanks, Sure.
pleased year with patients we're the ending XX,XXX of posted than treprostinil therapies. one patient full our of very more said, Martine and year to for on revenue XXXX, double-digit the have As growth
Tyvaso, treprostinil products, and of This into quarter, dive underlying three Remodulin I'd to the like Orenitram. our performance
going metrics, and pharmacy I'm revenue with ordering specialty on exactly our track As quarterly remind I'll to usual, quarterly always due everyone that patient underlying does to focus our our not patterns. treprostinil partner more demand patient
So I'll with Tyvaso. begin
As third therapy importantly of when access you to no to fourth and And in launch. path quarter, the may what the recognizes to our on quarter doubling number label that PH-ILD recall, was in call not we early XXX COVID-related quarter patients added close may to of referrals, number linear. XXXX, our be added a PH-ILD we double impacts the This to established the our X,XXX to prescriptions to Tyvaso highest indication by launch, and assumes initiation of active we and this patients the from is X,XXX had end XXXX. patient of Tyvaso approximately physician patient we goal Tyvaso the since which The was census. of
QX, as in patients begin Our fourth starts after many wait until to advanced therapies. which quarter is common were new opt patient than the the less holidays to
current therapy patients are and on Our get specialty these started partners working clear this quarter. the to during backlog pharmacy
the All time continued meantime, decision can't prior We still for eligible. care to federal three the PH-ILD period patient drivers to for in have anticipate between public therapy anticipate comment year. core if been access over the Medicare next and including but of regarding quarters. of necessary coverage continue health decision, coverage timing patients this are close last a reimbursement opportunity the year. the now predict coverage steps of completed, any We have assistance the the this our We to Tyvaso several and decision apply May CMS a program to Tyvaso to Tyvaso they work
the last I these think I mentioned on call.
be driver in program, middle channel decision of patients physicians PH-ILD that for for patient patients. Tyvaso CMS in year. PH-ILD we simply are apply the CMS think through growth though this coverage the a Tyvaso prescribing federal hearing our waiting we many may assistance their health will First, are coverage Even for before the care through
among to until the historical from educational over these and two Second, vast to in we prescribing base, prescriber next physicians of space. majority we Up see grow in the growth has PAH prescriptions beyond trial. from the Tyvaso treaters, and outreach and our continue Tyvaso this continued expect continue come now, particularly efforts as ILD quarters
as approval as there DPI untapped upcoming potential a growth. an to this yet is in lot of area. Tyvaso additional Tyvaso view the So catalyst we And finally,
launch Tyvaso year. by our While summer would said for a this we have we've been with FDA DPI an approval we of this as assuming been QX call, thrilled week, on
So nothing's preparations, upon launch and are regard. meantime, immediately will to that we really changed ready approval. completing In launch we our be the in
quarter. We saw accounts yet during patient another Orenitram. quarter to of fourth Moving record the
that of launch we're what with number despite has primarily trickling dual-eligible with an with launch launch the to finally, with generic year. of we before, driven uptick to we're subcutaneous by FREEDOM-EV more generic has the label now continued And discussed Remodulin robust we've prescribers is a believe As continued last expansion of play form the That have treprostinil this about generic the an transitions in strong performance on data. treprostinil pump our recent saw of of pleased to with the interactions we've down in in efforts. the transitioning generic those early IV received patients our bolus The XXXX, closely positive Medicaid immaterial quite been patients, launch out initial we Medicare to months. feedback generic Remunity able
patients achieve alarms, pump's Remunity, recently work with with our decision completed be in in a issues. the the pleased partner, we of Everything the have the we alarm patients momentum the with of in X,XXX As cases, are next can, the our To up, sensitive. wrap safety with DEKA, and the look not We Likewise, while forward the be progress testing feedback, to earlier. to is end that alarms as and PH-ILD. some recommence to we're an just we on May we're and will expected, of week. we're the year, We ensure that track clear, we're pump, for profile. rollout learned that physicians the Remunity optimize the overly working introduction issues pleased by to patients Tyvaso system. coverage final seeing or Orenitram. with with of part alarm To awesome new new continued we But CMS experience paused our on Tyvaso
introduction pump. despite of we the over that patients the once think our to with new back to will generic the turn Remunity call especially robust we that, Martine. And recommence Remodulin I'll competition, remain Finally, revenues
